Copy to clipboard 
Dark Horse Consulting Group (DHCG), a leader in strategic and operational biotherapeutics consulting, is pleased to announce the acquisition of Bruder Consulting & Venture Group (BCVG), a strategic advisory and consulting firm with a global footprint in biotech and biopharma, known for their expertise in the discovery, development, clinical design, and regulatory approval process of biologics, devices and combination products in the orthopedic, wound care, and plastic & reconstructive surgery markets. BCVG is now a department within DHCG known as DHC Regenerative Medicine.
This acquisition further strengthens DHCG’s patient-centered commitment to accelerating the development and commercialization of biotherapeutics by building out an integrated ecosystem of consulting services. The addition of BCVG extends the Group’s wide range of capabilities—following recent strategic expansions with BioTechLogic and Converge Consulting—to include regenerative medicine, tissue repair, and biomaterials.
“Welcoming Bruder into the Dark Horse family as our experts in Regenerative Medicine marks yet another meaningful milestone in our period of strategic growth,” said Anthony Davies, Ph.D., Founder and CEO of Dark Horse Consulting Group. “BCVG’s deep experience in regenerative medicine enriches our collective expertise and accelerates our capacity to deliver comprehensive solutions to developers and investors, thus moving therapies along further and faster for the ultimate benefit of patients worldwide.
Scott P. Bruder, M.D., Ph.D., Founder and CEO of BCVG, added: “Joining forces with DHC allows us to scale the expertise that our core team and advisors can provide, thus widening our opportunities to support Client Partners at all stages of the development process. Our expertise in the field of regenerative medicine will also add comprehensive additional value and service offerings to the Group’s current clients.”
Source: Dark Horse Consulting Group
